Biotechnology
Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2021
HONG KONG, Nov. 25, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...
2020-11-25 05:16
12964
NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound Symposium
TAIPEI, Nov. 24, 2020 /PRNewswire/ -- The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to theCOVID-19 epidemic. During the 5-day conference, participants presented and exchanged inf...
2020-11-24 22:26
1285
OliPass Announces Formation of Scientific Advisory Board of Pioneers in Sodium Ion Channellopathy and Pain
SEOUL, South Korea, Nov. 24, 2020 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to commission a Scientific Advisory Board ("SAB") of key experts in sodium ion channelopathy and pain. The SAB will advise OliPass on th...
2020-11-24 22:00
1954
New Centre for Medicines Research (CMR) Clinical Factbook From Clarivate Highlights Increasing Cost and Complexity of Phase II Trials
Pharmaceutical clinical industry report highlights factors impacting volume, cost and duration of Phase II trials LONDON, Nov. 24, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced t...
2020-11-24 16:05
7494
Sunway University Researcher Looks into Genomes and Allergies
KUALA LUMPUR, Malaysia, Nov. 24, 2020 /PRNewswire/ -- Dust mites, common in most human habitats are also one of the most common causes of allergies. Dr Kavita Reginald, Senior Lecturer from the Department of Biological Sciences at Sunway University has made it her interest to study these microscop...
2020-11-24 09:00
2624
Koru Lifescience preparing to send drug compounds to preclinical and clinical trials based on their study for Covid-19
AUCKLAND, New Zealand, Nov. 24, 2020 /PRNewswire/ -- Koru Lifescience, drug discovery, and advanced formulation research laboratory inAuckland, New Zealand , has identified several known drug compounds of value in their study for a treatment of Covid-19. The study reports shall be published after ...
2020-11-24 04:35
1042
3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212
SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company's partner, has commenced the phase III clinical program of a combination therapy involving SEL...
2020-11-23 21:28
10414
Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies
DAEJEON, South Korea and CASTRES, France, Nov. 23, 2020 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research. The decision has been acknowle...
2020-11-23 09:00
2308
Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange
HONG KONG, Nov. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leader in discovery, development and commercialization of innovative cancer medicines, today announced that the company was officially listed and it's shares commenced trading on the Main Board...
2020-11-20 21:09
13018
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy The Phase 3 study is expected to recruit up to 125 patients across approximately 40 U.S. clinical sites RHB-...
2020-11-20 21:00
5388
WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou
HANGZHOU, China, Nov. 20, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced its biologics integrated innovation center has been in operation inHangzhou, Zhejiang province, China. From process deve...
2020-11-20 16:30
2295
WPI-MANA Team: Biogenic Iron Sulfide Nanoparticles Enable Electron Uptake in Bacteria
TSUKUBA, Japan, Nov. 20, 2020 /PRNewswire/ -- A MANA team has identified the mechanism underlying the synthesis of long, electrically conductive pathways via iron sulfide (FeS) nanoparticles (NPs) in bacteria. This has implications in the development of new ways to inhibit microbial iron corrosio...
2020-11-20 14:00
1241
RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease
FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with demonstrated antiviral and potential tissue-protective effects The Phase 2/3 study is designed to evaluate outpatient-b...
2020-11-20 07:00
3284
Covis Group Announces Data for Ciraparantag Published in Blood, the Journal of the American Society of Hematology
Summarizes ciraparantag's expected mechanism of action, pharmacokinetic, and pharmacodynamic characteristics and its proof of concept as an anticoagulant reversal agent LUXEMBOURG and ZUG, Switzerland, Nov. 20, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") today announced that data demonst...
2020-11-20 01:26
2012
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction
BEIJING, Nov. 19, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merg...
2020-11-19 21:09
9140
RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib
Pre-scheduled independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia Enrollment in the 270-patient global Phase 2/3 COVID-19 study with opaganib is more than 50% complete ...
2020-11-19 20:21
4743
With Elekta Studio, Elekta brings complete image-guided brachytherapy workflow to a single room
VEENENDAAL, The Netherlands, Nov. 19, 2020 /PRNewswire/ -- Elekta (EKTA-B.ST) today introduced Elekta Studio with its launch of the ImagingRing, an advanced interventional CT system that revolves around the patient and enables clinicians to conduct the entire brachytherapy workflow - including ap...
2020-11-19 15:16
4259
Mibelle Biochemistry's Ability to Introduce Breakthrough Active Ingredients for the Personal Care Market Lauded by Frost & Sullivan
The company's active ingredient product lines meet consumer expectations of quality, performance, and sustainability LONDON, Nov. 18, 2020 /PRNewswire/ -- Based on its recent analysis of the global personal care active ingredients market, Frost & Sullivan recognizes Mibelle AG Biochemistry with t...
2020-11-18 23:40
2151
Deep Longevity Launches The First Longevity Medicine Course For Physicians
HONG KONG, Nov. 18, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; SEHK:0575.HK)'s Deep Longevity, Inc, a company subject to a conditional acquisition by the Group which is a pioneer in deep biomarkers of aging...
2020-11-18 23:00
9763
WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-The-Art Testing Laboratory
PHILADELPHIA, Nov. 18, 2020 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies industry – today announced the completion of a facility expansion that will triple its advanced testing capaci...
2020-11-18 21:00
1705
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
